Antifungal Selection for the Treatment of Onychomycosis: Patient Considerations and Outcomes.

Publication Year: 2024

DOI:
10.2147/IDR.S431526

PMCID:
PMC10922011

PMID:
38463386

Journal Information

Full Title: Infect Drug Resist

Abbreviation: Infect Drug Resist

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pharmacology & Pharmacy

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Disclosure Eden Axler reports no conflicts of interest in this work. Dr Shari Lipner reports grants from Moberg Pharmaceuticals, Belle Torus Corporation; personal fees from Hoth Therapeutics, Ortho Dermatologics, and Eli Lilly, outside the submitted work. Dr. Lipner has also served as a consultant for Ortho-Dermatologics, Eli Lilly, Moberg Pharmaceuticals, and BelleTorus Corporation."

Evidence found in paper:

"No funding was utilized in the preparation of this manuscript."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025